Find all the latest information
acute myeloid leukemia
, arranged by types, translocations, and mutations.
Listed below are recently updated categories.
American Society of Hematology 2020 treatment guidelines for older adults with AML
The American Society of Hematology (ASH) has established new treatment guidelines for newly diagnosed (ND) or...
FDA grants Oxi4503 rare pediatric disease designation for the treatment of children with AML
On September 16, 2020, the U.S. Food and Drug Administration (FDA) granted OXi4503 rare pediatric drug...
Addition of gemtuzumab ozogamicin to frontline 7+3: A case report
During the 2nd How to Diagnose and Treat Acute Leukaemia conference of the European School of Haematology (ESH), Juliette Lambert...
Addition of midostaurin to frontline 7+3: A case report
During the 2nd How to Diagnose and Treat Acute Leukaemia conference of the European School of Haematology (ESH), our AML Hub Executive Steering...
The effect of gemtuzumab ozogamicin on MRD and relapse in patients with NPM1-mutated AML
Advances in the molecular assessment of measurable residual disease (MRD) in patients with acute myeloid...
IDHENTIFY phase III trial fails to meet primary end point
On August 25, 2020, it was announced that the phase III IDHENTIFY trial (NCT02577406), evaluating enasidenib plus best supportive care (BSC)...
Gemtuzumab ozogamicin for salvage CBF-AML: A case report
During the 2nd How to Diagnose and Treat Acute Leukaemia conference organized by the European School of Haematology (ESH), there was an...
LDAC plus AC220: Results from the LI-1 trial in older patients with AML
During the 25th European Hematology Association (EHA) Annual Congress 2020, Mike Dennis presented an oral abstract on the...
Core binding factor
Epigenetic modifier mutations
Signaling pathway mutations
Transcription factor mutations
Tumor suppressor mutations